GenSight Biologics S.A.

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

With the US Inflation Reduction Act threatening a major shake-up in drug pricing from 2023 onwards, and with the progress of increasing numbers of costly advanced therapeutics onto the market, one thi

Paris, France-based biotech HORAMA is relaunching itself as Coave Therapeutics, and a €33.1m ($39m) series B fundraising to help accelerate its progress in the competitive world of gene therapy. The

The European Medicines Agency has added eight new medicines to its list of investigational products that are under review for potential pan-EU marketing approval. These include abrocitinib, Pfizer ’s